# A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

> **NCT03555305** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 58 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Insulin Glargine
- **DRUG:** Lantus

## Key facts

- **NCT ID:** NCT03555305
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-26
- **Primary completion:** 2019-11-04
- **Final completion:** 2019-11-04
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2020-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555305, "A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03555305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*